CA3069921C - Methods of treating autoimmune microvascular disorders - Google Patents

Methods of treating autoimmune microvascular disorders Download PDF

Info

Publication number
CA3069921C
CA3069921C CA3069921A CA3069921A CA3069921C CA 3069921 C CA3069921 C CA 3069921C CA 3069921 A CA3069921 A CA 3069921A CA 3069921 A CA3069921 A CA 3069921A CA 3069921 C CA3069921 C CA 3069921C
Authority
CA
Canada
Prior art keywords
subject
diosmin
therapeutically effective
pharmaceutically acceptable
systemic sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3069921A
Other languages
English (en)
French (fr)
Other versions
CA3069921A1 (en
Inventor
Robert M. Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PRIMUS PHARMACEUTICALS Inc
Original Assignee
PRIMUS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PRIMUS PHARMACEUTICALS Inc filed Critical PRIMUS PHARMACEUTICALS Inc
Publication of CA3069921A1 publication Critical patent/CA3069921A1/en
Application granted granted Critical
Publication of CA3069921C publication Critical patent/CA3069921C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3069921A 2017-07-19 2018-07-18 Methods of treating autoimmune microvascular disorders Active CA3069921C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762534237P 2017-07-19 2017-07-19
US62/534,237 2017-07-19
PCT/US2018/042573 WO2019018455A1 (en) 2017-07-19 2018-07-18 METHODS OF TREATING AUTOIMMUNE MICROVASCULAR DISORDERS

Publications (2)

Publication Number Publication Date
CA3069921A1 CA3069921A1 (en) 2019-01-24
CA3069921C true CA3069921C (en) 2022-01-18

Family

ID=65016682

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069921A Active CA3069921C (en) 2017-07-19 2018-07-18 Methods of treating autoimmune microvascular disorders

Country Status (12)

Country Link
US (2) US11278517B2 (https=)
EP (2) EP3654965B1 (https=)
JP (1) JP7237962B2 (https=)
KR (1) KR102717665B1 (https=)
CN (1) CN111065389B (https=)
AU (1) AU2018304208B2 (https=)
CA (1) CA3069921C (https=)
ES (1) ES2957742T3 (https=)
HR (1) HRP20231517T1 (https=)
MX (1) MX2020000625A (https=)
PL (1) PL3654965T3 (https=)
WO (1) WO2019018455A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306300A (zh) * 2022-01-04 2022-04-12 上海交通大学医学院附属仁济医院 一种香叶木素的用途及其动物模型的建立方法
WO2026014965A1 (ko) * 2024-07-11 2026-01-15 한국 한의학 연구원 한련초 추출물 유래 화합물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
CA2875522A1 (en) * 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
FR2929276B1 (fr) 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10596185B2 (en) 2014-03-31 2020-03-24 Ingredients By Nature Flavonoid compositions and uses thereof

Also Published As

Publication number Publication date
AU2018304208A1 (en) 2020-02-13
US11844777B2 (en) 2023-12-19
JP7237962B2 (ja) 2023-03-13
PL3654965T3 (pl) 2024-02-26
EP3654965A1 (en) 2020-05-27
CN111065389B (zh) 2023-11-21
KR20200051579A (ko) 2020-05-13
EP4269397A3 (en) 2024-01-31
WO2019018455A1 (en) 2019-01-24
US11278517B2 (en) 2022-03-22
KR102717665B1 (ko) 2024-10-14
ES2957742T3 (es) 2024-01-24
EP3654965A4 (en) 2021-03-10
AU2018304208B2 (en) 2022-03-17
CA3069921A1 (en) 2019-01-24
JP2020528454A (ja) 2020-09-24
EP3654965C0 (en) 2023-09-06
EP3654965B1 (en) 2023-09-06
US20220168267A1 (en) 2022-06-02
HRP20231517T1 (hr) 2024-03-01
US20200147031A1 (en) 2020-05-14
EP4269397A2 (en) 2023-11-01
MX2020000625A (es) 2020-09-28
CN111065389A (zh) 2020-04-24

Similar Documents

Publication Publication Date Title
CA2267049A1 (en) Pharmaceutical compositions
KR20090034810A (ko) 멜라토닌 효능제 치료
US11844777B2 (en) Methods of treating autoimmune microvascular disorders
Agrawal et al. Randomized controlled pilot trial of nifedipine as oral therapy vs topical application in the treatment of fissure-in-ano
JP2013533253A (ja) 双極性障害を治療する方法
Fischer et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat
MD3347002T2 (ro) Tratamentul bolii Alzheimer într-o populație specifică de pacienți
JP5727642B2 (ja) センタキンを用いた新規の治療方法
AU2021388141A9 (en) Treatment of raynaud's disease
ES2237625T3 (es) Uso de un derivado de hidantoina en una composicion farmaceutica contra la hipoalbuminemia.
EP3976012B1 (en) Intranasal administration of ketamine to cluster headache patients
Lagacé et al. Newer and Safer Kappa-Opioid Agonist for Your Patients With Uremic Pruritus
AU2005239799B2 (en) Sustained-release oral molsidomine composition for treating atherosclerosis
RU2304964C2 (ru) Способ лечения хронической сердечной недостаточности
NEBIVOLOL Gender Differences/Issues P-477
Charleston Valsartan monotherapy reduces hs-CRP levels
KR20120067783A (ko) 섬유근육통 치료용 의약 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200113